What Does Entrada Therapeutics Do?

Total employees214
HeadquartersBoston
Founded2016

Entrada Therapeutics, Inc. (NASDAQ: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients with devastating diseases by developing and commercializing a new class of medicines, Endosomal Escape Vehicle (EEV™) therapeutics. Their proprietary EEV platform is designed to enable the intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, with an initial focus on neuromuscular diseases. Entrada's lead product candidate, ENTR-601-44, is in clinical development for patients with Duchenne muscular dystrophy (DMD) who are exon 44 skipping amenable. They are also advancing a pipeline of other EEV-based programs for neuromuscular and other diseases.

Where Is Entrada Therapeutics's Headquarters?

HQ Function

Primary hub for research and development, clinical operations, and corporate administration, driving the company's mission to develop EEV-based therapeutics.

Notable Features:

Modern, state-of-the-art laboratory and office facilities designed to foster collaboration and innovation in a prime biotech location.

Work Culture:

A dynamic and science-focused environment encouraging collaboration, innovation, and a strong commitment to addressing unmet patient needs. Employees often experience a fast-paced setting typical of growth-stage biotechnology companies focused on groundbreaking science.

HQ Significance:

Strategically located in Boston's Seaport District, a vibrant biotechnology hub, providing access to leading talent, research institutions, and potential collaborators. Its presence here underscores its commitment to cutting-edge science and development.

Values Reflected in HQ: The investment in advanced research facilities reflects a commitment to scientific excellence and innovation. The collaborative workspace design supports teamwork, a key value in tackling complex diseases and advancing their EEV platform.

Location:

While headquartered and primarily operating its research and development in Boston, USA, Entrada Therapeutics has a global outlook. Its clinical trial operations for its therapeutic candidates, such as ENTR-601-44 for Duchenne muscular dystrophy, are designed to include international sites. The company aims to address diseases affecting patients worldwide and engages with global regulatory authorities and potential partners to advance its mission.

Street Address:

22 Boston Wharf Road, 7th Floor

City:

Boston

State/Province:

MA

Country:

USA

Where Else Does Entrada Therapeutics Operate Around the World?

No additional office locations available.

Buying Intent Signals for Entrada Therapeutics

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Entrada Therapeutics? Meet the Executive Team

As of April 2025, Entrada Therapeutics' leadership includes:

Dipal Doshi, M.B.A. - President and Chief Executive Officer
Nerissa Kreher, M.D., M.S., M.B.A. - Chief Medical Officer
Kory Wentworth, CPA - Chief Financial Officer
Nathan Dowden, M.B.A. - Chief Operating Officer
Mary Phelan, M.S. - Chief People Officer
Tia L. Keyes, J.D. - Chief Legal Officer and Corporate Secretary

Who's Investing in Entrada Therapeutics?

Entrada Therapeutics has been backed by several prominent investors over the years, including:

5AM Ventures
MPM Capital
Roche Venture Fund
Vertex Ventures HC
Wellington Management
Greenspring Associates (now part of StepStone Group)
Omega Funds
Cowen Healthcare Investments (now part of TD Cowen)

What Leadership Changes Has Entrada Therapeutics Seen Recently?

Hire5
Exits0

In the past 12 months, Entrada Therapeutics significantly strengthened its executive leadership team with several key appointments in August 2023, including a new Chief Medical Officer, Chief Financial Officer, Chief People Officer, and Chief Legal Officer, alongside the promotion of its Chief Operating Officer. No major executive departures were publicly announced during this period.

New Appointments:

Nerissa Kreher, M.D., M.S., M.B.A., Nerissa Kreher appointed as Chief Medical Officer.
Kory Wentworth, CPA, Kory Wentworth appointed as Chief Financial Officer.
Mary Phelan, M.S., Mary Phelan appointed as Chief People Officer.
Tia L. Keyes, J.D., Tia L. Keyes appointed as Chief Legal Officer and Corporate Secretary.
Nathan Dowden, M.B.A., Nathan Dowden promoted to Chief Operating Officer.

What Technology (Tech Stack) Is Used byEntrada Therapeutics?

Discover the tools Entrada Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Entrada Therapeutics Email Formats and Examples

Entrada Therapeutics likely uses common corporate email formats. The most probable patterns are [firstinitial][last]@entradatx.com or [first].[last]@entradatx.com. For example, an employee named Jane Doe might have an email address like jdoe@entradatx.com or jane.doe@entradatx.com.

[firstinitial][last]@entradatx.com (e.g., jdoe@entradatx.com), [first].[last]@entradatx.com (e.g., jane.doe@entradatx.com)

Format

jdoe@entradatx.com

Example

80%

Success rate

What's the Latest News About Entrada Therapeutics?

GlobeNewswireFebruary 27, 2024

Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Entrada Therapeutics announced its financial results for Q4 and full year 2023, highlighting progress with its EEV-therapeutics pipeline, including updates on the Phase 1 clinical trial for ENTR-601-44 in Duchenne muscular dystrophy and plans for its myotonic dystrophy type 1 program....more

GlobeNewswireJanuary 4, 2024

Entrada Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of ENTR-601-44 for Duchenne Muscular Dystrophy

The company announced the dosing of the first participant in its Phase 1 clinical trial (MAVERICK) of ENTR-601-44, an EEV-conjugated phosphorodiamidate morpholino oligomer (PMO) for Duchenne muscular dystrophy patients amenable to exon 44 skipping....more

GlobeNewswireNovember 9, 2023

Entrada Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Entrada reported its Q3 2023 financial results, noting the U.S. FDA clearance of the Investigational New Drug (IND) application for ENTR-601-44 and providing updates on its research pipeline and corporate strategy....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Entrada Therapeutics, are just a search away.